Bryan Giraudo
Bryan Giraudo's purchase track record
How the stock did after each of Bryan Giraudo's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/18/2024 | GOSS | $59K | +65.9% | +61.1% | +10.3% |
| 11/13/2023 | GOSS | $113K | +39.7% | +14.3% | +18.4% |
| 4/4/2023 | GOSS | $56K | +26.1% | -28.5% | +3.1% |
| 3/20/2023 | GOSS | $48K | +8.7% | -22.1% | +12.7% |
| 7/15/2022 | GOSS | $100K | +9.8% | -78.9% | +3.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
GOSS Submits NDA for Seralutinib in Pulmonary Arterial Hypertension. Gossamer Bio has filed a new drug application with the U.S. FDA for Seralutinib, a treatment aimed at pulmonary arterial hypertension. The filing follows a broader after‑market move in health‑care stocks, with GOSS among the 12 that saw activity Friday. The submission could influence the company’s future regulatory path and investor interest.
Transaction History
| PTGX | ▼ Sell | Open Market | 6,000 | $600K | 5/8/2026 | View on chart |
| PTGX | ▼ Sell | Open Market | 5,130 | $513K | 5/8/2026 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 24,000 | $155K | 5/7/2026 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 12,000 | $84K | 5/7/2026 | View on chart |
| PTGX | ▼ Sell | Open Market | 36,000 | $3.6M | 5/7/2026 | View on chart |
| PTGX | ▼ Sell | Open Market | 12,000 | $1.2M | 5/7/2026 | View on chart |
| PTGX | ▲ Buy | Grant | 2,695 | $0 | 1/2/2026 | View on chart |
| GOSS | ▲ Buy | Grant | 115,750 | $0 | 1/2/2026 | View on chart |
| GOSS | ▲ Buy | Grant | 181,250 | $0 | 10/1/2025 | View on chart |
| PTGX | ▲ Buy | Grant | 5,130 | $0 | 1/2/2025 | View on chart |
| GOSS | ▲ Buy | Open Market | 100,000 | $59K | 6/18/2024 | View on chart |
| GOSS | ▼ Sell | Open Market | 6,430 | $7K | 3/27/2024 | View on chart |
| GOSS | ▲ Buy | Open Market | 200,000 | $113K | 11/13/2023 | View on chart |
| GOSS | ▲ Buy | Grant | 54,020 | $98K | 7/24/2023 | View on chart |
| GOSS | ▲ Buy | Open Market | 55,000 | $56K | 4/4/2023 | View on chart |
| GOSS | ▲ Buy | Open Market | 50,000 | $48K | 3/20/2023 | View on chart |
| GOSS | ▲ Buy | Open Market | 13,869 | $100K | 7/15/2022 | View on chart |
| GOSS | ▼ Sell | Open Market | 10,722 | $96K | 3/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
PTGX featured in recent SeekingAlpha and Benzinga articles
A SeekingAlpha column noted Johnson & Johnson’s strong catalysts while keeping a hold stance, a view that may influence sentiment toward biotech peers such as Protagonist Therapeutics. Separately, Benzinga published a piece examining how a $100 investment in PTGX ten years ago would have grown, highlighting the stock’s historical performance. These mentions reflect ongoing analyst and investor interest in the company.
PTGX featured in recent SeekingAlpha and Benzinga articles. A SeekingAlpha column noted Johnson & Johnson’s strong catalysts while keeping a hold stance, a view that may influence sentiment toward biotech peers such as Protagonist Therapeutics. Separately, Benzinga published a piece examining how a $100 investment in PTGX ten years ago would have grown, highlighting the stock’s historical performance. These mentions reflect ongoing analyst and investor interest in the company.